Editors' report, November 2013
Harms from medicines: inevitable, in error or intentional
Structure-based drug design of catechol-O-methyltransferase inhibitors for CNS disorders
Challenges posed to the European pharmaceutical regulatory system by highly personalized medicines
What are validated self-report adherence scales really measuring?: a systematic review
The PlA1/A2 polymorphism of glycoprotein IIIa in relation to efficacy of antiplatelet drugs: a systematic review and meta-analysis
Statin use and risk of kidney cancer: a meta-analysis of observational studies and randomized trials
A repeat-dose thorough QT study of inhaled fluticasone furoate/vilanterol combination in healthy subjects
Population pharmacokinetic analysis of axitinib in healthy volunteers
Comparison of intracellular methotrexate kinetics in red blood cells with the kinetics in other cell types
How to manage intravenous vinflunine in cancer patients with renal impairment: results of a pharmacokinetic and tolerability phase I study
Population pharmacokinetics of ampicillin and sulbactam in patients with community-acquired pneumonia: evaluation of the impact of renal impairment
Are women more susceptible than men to drug-induced QT prolongation? Concentration–QTc modelling in a phase 1 study with oral rac-sotalol
Population pharmacokinetic/pharmacodynamic modelling of eltrombopag in healthy volunteers and subjects with chronic liver disease
Adverse drug reactions and off-label and unlicensed medicines in children: a prospective cohort study of unplanned admissions to a paediatric hospital
Expansion of a PBPK model to predict disposition in pregnant women of drugs cleared via multiple CYP enzymes, including CYP2B6, CYP2C9 and CYP2C19
High dose benzodiazepines prolong reaction times in chronic users who have major depressive and/or anxiety disorders
Instantaneous rigor after fatal pholcodine intoxication
Little soldiers in their cardboard cells
World-class cyclists on erythropoietin